Current perspectives in tackling glaucoma blindness

Abstract

As a major reason for irreversible vision loss, glaucoma is a significant public health concern. Its multifactorial nature demands a nuanced understanding of its pathophysiology, risk factors, and management. An understanding, and continuous refinement, of diagnostic and therapeutic modalities, including pharmacological interventions, novel methods of drug delivery, and surgical techniques (including minimally invasive glaucoma surgeries) are critical. The advent of personalized medicine, genetic profiling, and innovative biomarkers for identifying susceptible individuals and tailoring treatment strategies may help prevent blindness and improve patient outcomes. Evaluation of the impact of lifestyle modifications and holistic approaches and integration of telemedicine and artificial intelligence in glaucoma management may revolutionize current glaucoma practice. In addressing the global challenge of glaucoma blindness, this narrative review highlights ongoing initiatives, public health policies, and community-based interventions. This includes raising awareness, enhancing early detection programs, and access to care, particularly in underserved populations.

Glaucoma is an optic neuropathy due to axonal injury, leading to paucity of neurotrophic growth factors and death of retinal ganglion cells (RGCs).[1] Typically, glaucoma patients remain asymptomatic until later in the disease, when the loss of vision is usually irreversible. Reducing intraocular pressure (IOP) is known to delay progression and preserve visual fields in both primary open-angle and primary angle closure glaucoma (POAG and PACG, respectively).[2,3,4]

Understanding the burden of glaucoma may provide valuable insight for health policy formulation and allocation of resources. The global socioeconomic burden of glaucoma continues to rise, with an age-standardized prevalence estimated at approximately 3–5% among individuals over 40 years. This prevalence is projected to reach 112 million people by 2040.[4] The Global Burden of Diseases Study (GBD) indicates a notable increase in prevalent cases of glaucoma from an estimated 3.88 million 1990 to 7.45 million in 2019 globally. During the same period, disability-adjusted life years (DALYs) associated with glaucoma rose from 442,182 in 1990 to 748,308 in 2019. Notably, a significant negative correlation has been observed between the sociodemographic index and DALY rates adjusted for age.[5] In 2020, an estimated 3.6 million individuals more than 50 years of age were afflicted with glaucoma, making it the second most important reason for vision impairment, the first being cataract.[6]

This review aims to elucidate recent advances in understanding the pathophysiology and management of glaucoma to reduce its future global burden.

PubMed, Embase, Ovid, Scopus, and Trip databases were systematically searched until January 1, 2024 to assess relevant articles and continued research endeavors. The search employed keywords such as glaucoma, POAG, PACG, optical coherence tomography (OCT), OCT angiography, perimetry, artificial intelligence, nanomedicines, neuroenhancement, and neuroprotection. All articles curated for relevance, and reference lists and additional keywords of the chosen articles were scrutinized for any inadvertent misses. The articles so found were also included and cross-referenced.

Advances in Glaucoma Pathophysiology

Traditionally, pathogenesis of glaucomatous optic neuropathy has been attributed to elevated IOP, ischemia, and/or reperfusion retinal injury or due to direct neuronal death secondary to excitotoxicity, oxidative stress, and so on. Risk factors for glaucoma include advancing age, male gender, African ancestry, elevated IOP, thin central corneal thickness (CCT), elevated cup disc ratios, a positive family history of glaucoma, smoking, sleep apnea, metabolic diseases like diabetes mellitus, and both high and low blood pressures.

Emerging associations include newer genetic influences, neurodegenerative and neuroinflammatory cerebral changes, neuroinflammation, mitochondrial abnormalities, and translaminar pressure dynamics.[7,8]

“Brain diabetes theory” suggests that glaucoma is type 4 diabetes – a dysfunction of central insulin signalling, leading to transsynaptic neurodegeneration.[9] Insulin resistance, and the consequent metabolic syndrome, may increase the risk of glaucoma,[10] especially normal tension glaucoma.[11]

Alteration in neurotrophin signaling pathway results in a higher risk of misfolded protein aggregation in endoplasmic reticulum, eventually increasing the rate of RGC apoptosis. Genes associated with the neurotrophin signaling pathways are associated with glaucoma.[12]

Adaptive immunity

New evidence indicates a link between increased IOP and T-cell-mediated autoimmune responses, wherein heat shock proteins act as pathogenic autoantigens, underlying the neurodegeneration.[13] Reactive glial responses and low-grade inflammation occur due to proinflammatory cytokines (IL-6, IL-1β, TNF-α) in the retina in response to stress. Sustained and excessive glial reactions result in exaggerated immune responses via toll-like receptors 2 and 4, eventually leading to progressive neuronal damage and vision loss.[14]

Emerging Diagnostic Tools

Advances in conventional SAP; SITA FASTER 24-2C

Traditionally, standard automated perimetry (SAP) is performed using the 24-2 and 30-2 protocols. SITA Faster 24-2C (SFR-C) includes ten additional points in the macular area, changes in which impact daily activities the most.[15] Shorter test duration of SFR-C improves its reliability, with reduced patient fatigue. Both SFR-C and 10-2 test grids yield comparable global indices for evaluation of visual fields and show proportionate levels of visual field loss.[16]

Tablet perimetry

SAP equipment is costly and necessitates a dedicated testing environment. Tests of the visual field utilizing tablets and virtual reality (VR) headsets have, therefore, gained popularity. The Melbourne Rapid Fields (MRF) application allows visual field assessment as either full threshold test (4–5 minutes/eye) or a screening test (90 seconds/eye). The online perimeter application, accessible via cloud, uses a full test or a modified 24-2 grid, centered at fixation, that covers 30° ×20° of the visual field. MRF may thus be more cost-effective and user-friendly in areas with limited access to healthcare.[17,18,19]

Virtual reality perimetry in clinical setting

Virtual reality perimetry (VRP) can be used to map VF defects conveniently. Currently available VR perimeters include VIP Visual Fields (Arieh Solomon, Tel Aviv, Israel), Vivid Vision Perimetry (Vivid Vision Inc.), imo by Matsumoto et al.,[20] Virtual Field (Virtual Field Inc), Visual Field Visualizer by Nguyen et al.,[21] VR eCloud Perimeter by Ashvin Agarwal et al., and numerous others.[22]

OCT Angiography (OCTA)

Precapillary and capillary dysregulation may impact glaucoma pathogenesis and progression, and vascular changes can both predate and predict neuronal damage. OCTA helps in a comprehensive analysis of capillary perfusion. Structural RNFL measurements on SDOCT along with information about capillary density and choroidal microvasculature dropouts may detect early alterations in the ONH and peripapillary area. This can help assess risk of glaucoma and its progression.[23,24]

Artificial intelligence (AI) in glaucoma

AI and Big Data can revolutionize glaucoma screening, diagnosis, and classification by automated analysis of extensive and diverse datasets, encompassing both structured and unstructured data, picking up any changes in disease patterns earlier.[25] However, no AI systems have received regulatory authorization for glaucoma yet. Phene et al.[26] have developed a standardized set of optic nerve morphological features that can aid in classifying a nerve as “referable optic disc,” utilizing the Google Health database. Application of AI algorithms to OCT is not as straight forward as fundus photography due to differential image acquisition, its registration and storage, and the protocols for processing. Most available algorithms can evaluate only one OCT device or scan and therefore cannot be used in real-world clinical settings.[27]

Even with feature-agnostic approaches, AI alone cannot diagnose glaucoma with certainty. Reasons include variability of RNFL thickness, effect of refraction and axial length on RNFL morphology, cyclotorsion of eye, fallaciously higher nerve fiber recordings because of gliosis, myelinated nerve fibers, edema, or falsely decreased RNFL thickness because of peripapillary atrophy.

AI algorithms that analyze structural tests like OCT have been able to reproduce and predict the corresponding losses in visual fields. These algorithms may thus predict loss of function even in those patients who cannot undergo visual field testing.[28] Though AI cannot obviate the practical problems of conventional perimetry or flatten the learning curve for reliable fields, deep learning (DL) algorithms can make interpretation easier.[29]

Most progression detection models assume that glaucoma progresses linearly and use statistical methods based on linear regression, although in advanced stages glaucoma progression may be nonlinear and rapid. Clustering analyses have been used to assess the visual field indices generated by the DL model longitudinally to predict glaucoma progression.[30]

Innovations in Medical Therapy

Rho Kinase inhibitors

Rho kinase inhibitors increase aqueous outflow relaxing smooth muscle fibers of the trabecular meshwork (TM) and reduce the resistance to outflow by increasing formation of pores in the endothelium in Schlemm’s canal (SC), resulting in decreased eye pressures.[31] These antiglaucoma medications (AGMs) may have a neuroprotective role because of augmented optic nerve perfusion. They may also decrease scarring following surgery.

Two commonly used ROCK inhibitors are ripasudil (0.4%) and netarsudil (0.02%). The former is used 12 hourly, and the latter once at bedtime. The most common side effects include conjunctival hyperemia (three in four) and blepharitis (one in five). Cornea verticillata is seen in patients using netarsudil alone.

Netarsudil is also available as a fixed dose combination with latanoprost 0.005%, which has shown more IOP reduction than either drug. The latest ROCK inhibitor still to reach the market is fasudil, which has shown an effective IOP decrease in advanced glaucoma.[32] Fasudil-loaded polylactide-co-glycolide (PLGA) microspheres have been proposed as depot injection for intravitreal use in patients with coexistent retinal disease.[33]

Latanoprostene bunod (LBN)

Latanoprostene bunod 0.024% is a prodrug, which donates nitric oxide (NO). It is metabolized to latanoprost acid and butanediol mononitrate (eventually to butane diol and NO).[34] The former increases uveoscleral outflow via the Prostaglandin F receptor, and via the matrix metalloproteinases (MMPs), it remodels the ciliary muscle extracellular matrix. NO causes vasodilation and relaxation of the smooth muscles in the TM and SC by decreasing cell volume and contraction, thus augmenting outflow facility.

Injectable AGMs and undertrial punctal plug delivery systems

Table 1 lists the AGMs which may be used via injectable or punctal plug delivery systems.[35]

Table 1.

Injectable systems and undertrial punctal plug delivery systems

Drug Delivery System	Drug	Material	Placement of location	Current stage of development
ENV515/PGA or Travoprost XR	Travoprost	-	Iridocorneal Angle	Phase 2 clinical trial
Bimatoprost SR	Bimatoprost	-	Subconjunctival space	Phase 3 clinical trial
Graybug	Various	-	Ocular Surface	Preclinical
OTX-TP	Travoprost	Polyethylene Glycol-Based Hydrogel with loaded PLA	Puncta	Phase 2 clinical trial
Evolute	Latanoprost	-	Puncta	Phase 2 clinical trial
Latanoprost Punctal Plug Delivery System (L-PPDS)	Latanoprost	-	Puncta	Phase 2 clinical trial

Nanotechnology: Nanomedicine formulations may improve adherence and patient quality of life (QoL). This is because of targeted drug delivery and consequent improvement in bioavailability. Sustained release AGMs and antimetabolite (in glaucoma surgeries) dosing, can improve compliance and, consequently, clinical outcomes.[35]

Nanoparticle injections of dorzolamide (subconjunctival), brimonidine (supraciliary), and intravitreal nanosponges loaded with brimonidine, travoprost, and bimatoprost have all been tried but are yet to be used in current clinical practice.[36]

Neuroenhancement and neuroprotection

Mitochondrial abnormalities may result in neuronal dysfunction in glaucoma.[37] An age-dependent decline occurs in the nicotinamide adenine dinucleotide (NAD), an important reduction–oxidation cofactor that increases the susceptibility of the RGCs to increased eye pressures. Serum levels of nicotinamide (NAM; an NAD precursor) are also decreased in glaucoma patients.[38] Therefore, neuroprotective agents that target NAD and bioenergetic capacity and consequently increase the RGC resilience may be the next frontier for glaucoma therapy.

NAM has a proven safety and tolerability profile at even high doses.[39] De Moraes et al.[40] have shown that increasing oral doses of nicotinamide (NAM, 1–3 g, Vitamin B3) along with pyruvate (1.5–3 g) caused notable enhancements in short-term vision. The study revealed a significantly greater improvement within the treatment group in comparison to placebo. Furthermore, the rate of change in pattern standard deviation (PSD) was notably more favorable in the former (−0.06 versus 0.02 dB/week). No significant alteration was observed in mean deviation (MD) or visual field index (VFI). NAD enhances the neuroprotection of glaucoma by varying effects on healthy and diseased RGCs.[41] Given that NAD’s effects are not solely directed at diseased RGCs, it is essential to investigate its impact on the unaffected RGCs.

Additionally, specific approaches such as gene silencing and use of stem cells are positioned to play significant roles glaucoma therapeutics.

Adherence: Despite the progress made in pharmacotherapy for glaucoma, adherence and compliance with glaucoma medications remain fundamental challenges, with approximately 24 to 59% of patients failing to adhere to their prescribed regimens.[42,43,44] Glaucoma Adherence and Persistency Study elucidates the salient factors that could be the possible barriers to compliance. In addition to decreasing drug costs, education and motivation play a major role may result in better adherence to medication.

Innovations in Surgery

Minimally Invasive Glaucoma Surgery (MIGS): The transition from pharmacotherapy to conventional filtering surgery or drainage device implantation is now bridged by less invasive, ab interno, conjunctiva sparing, MIGS. Most MIGS procedures overcome the aqueous outflow resistance at the TM and SC. This restores the physiological outflow and may thus mean a few drug-free years for patients. MIGSs have a learning curve in terms of use of the direct gonioscope for visualization, angle anatomy, and orientation.

In early and moderate POAG, antiglaucoma drugs and selective laser trabeculoplasty (SLT) treatment are preferred treatment options; however, some patients have poor compliance or are intolerant to medicines or are not adequately controlled with drugs/SLT. MIGS procedures like iStent, Kahook Dual blade (KDB) goniotomy, Trabectome, and Hydrus offer a good reduction in IOP and number of AGMs. In advanced POAG, target IOP is typically in lower teens, and so, MIGS may not be preferred.[45]

When evaluating the cost-effectiveness of any glaucoma surgical intervention, various factors must be considered, including the cost of the procedure(s), efficacy measured by the reduction in the need for AGMs or follow-up visits, and comparing the one-time procedural expense with the overall expense of medications over the treatment period. Use of multiple devices (e.g., multiple iStents) or a combination of devices is recommended, potentially rendering it a costly option for many patients.[46] Trabecular bypass shunts have demonstrated cost-effectiveness compared to standard care, accompanied by improvements in quality of life.[47]

Currently, not all MIGS procedures are available in India. Most of the MIGSs that target the TM are the low-cost versions of their Western counterparts, for example, using prolene suture in GATT for 360° unroofing of SC versus OMNI® Glaucoma Treatment System and use of a bent needle for Bent-needle Ab-interno Goniectomy (BANG) instead of KDB. However, trabeculectomy continues to be the gold standard, most performed, as well as the cheapest surgical procedure.[48,49]

Telemedicine and Remote Monitoring: Current Status, Challenges, and Future Directions

Telemedicine for glaucoma consultations: Teleglaucoma

Teleglaucoma screening protocols aim to detect early glaucoma, especially in high-risk, underserved populations. Traditional teleglaucoma relies on data collection (IOP, ONH imaging, and visual fields) by technicians at satellite centers or outreach clinics and asynchronous review by ophthalmologists in virtual clinics.[50] They also identify patients who require priority treatment and referral. COVID-19 crisis was the litmus test for teleglaucoma, enabling patients to access care.[51,52,53]

By leveraging new diagnostic technologies for remote and home monitoring of key clinical indicators, coupled with AI to support clinical decision making, teleglaucoma may revolutionize not just screening but also diagnostic and monitoring consultations.[54]

Collaborative telemedicine depends on collaborative partnerships between healthcare providers with different resources, in terms of expertise, equipment, and patient access. A patient may be referred to secondary or tertiary care as required, increasing the financial feasibility of the program.

In-house telemedicine is the least resource-intensive. Ophthalmologists utilize their own staff and equipment to provide remote care. Digitally integrated visits are a subset of this: Some patient visits are limited to glaucoma investigations, performed by technical personnel. The results are reviewed by the glaucoma specialists who modify care plans as required.

There are no regulatory standards for teleglaucoma, but its use is rational in patients with early disease for screening where it reduces the burden of false positives as well as monitoring of stable patients. With improved data collection, transfer, and interpretation, teleglaucoma may revolutionize the logistical implications of glaucoma care. It can decrease the need for in-person consultations, increasing patient satisfaction, saving time, costs, and travel for patients, without compromising clinical outcomes.[51,52]

Remote monitoring devices for IOP and visual field

Visual acuity testing: The visual acuity tests that are accepted for self-administration or remote use include the self-administered ETDRS visual acuity test and the free-to-download Home Acuity Test (www.homeacuitytest.org). Several application-based tests including the Peek Acuity app (Peek Vision; Android devices only), Accustat, and the OdySight app (Tilak Healthcare; Apple devices only) also show promise.[55,56,57,58] Automated target scaling and distance sensing, along with ease of use, are critical in minimizing the discrepancies between home measurement and standard clinical vison tests.

Tonometry: Several hand-held, portable self-monitoring devices have been validated for clinical use; these include the Tonopen and the iCare home tonometer.[59,60,61] The disposable Sensimed Triggerfish (Sensimed) contact lens sensor (CLS) captures corneoscleral changes as a marker for IOP changes and enables continuous 24-hour IOP monitoring.[62] The Eyemate (Implandata Ophthalmic Products) is a surgically implanted suprachoroidal sensor. Coupled with the Eyemate reader, it enables the patient to record their IOP.[63,64] Both Triggerfish CLS and Eyemate readings are transmitted to the physicians’ computer, enabling reliable telemonitoring of IOP.

Future research is directed toward developing the ideal IOP biosensor: one that is safe, accurate, biocompatible, and easy to use.[65] Nanoparticle and nanofiber-based contact lenses and biosensors hold great promise, together with the use of cloud platforms for remote monitoring of IOP.

Home visual field testing: VR-based perimeters are cost-effective, user-friendly, and faster than conventional perimetry. Their results, however, are less reliable in the home setting due to lack of standardization of ambient illumination, viewing distance, and fixation stability. Head-mounted VR perimeters are equipped with eye-tracking technology which improves fixation and, consequently, repeatability.[66] They are cheaper and faster, but so far, their comparison with standard perimetry has shown variable outcomes with respect to pointwise sensitivities, even though the global results show good correlation. A recent review evaluated 64 studies that evaluate 36 VR headset perimetry devices and concluded that VR perimetry has emerged as an effective, cost-effective, and well-tolerated option for glaucoma patients in terms of ease of gaze fixation and accessibility for patients with limited mobility.[67,68]

Digital photography: Individuals residing in far flung areas often have limited access to quality eyecare centers equipped with advanced diagnostic tools capable of detecting early signs of glaucomatous damage. The use of smartphones for glaucoma screening holds significant promise in facilitating early diagnosis and treatment. Various adapters can enable smartphone cameras to image the anterior segment as well as the fundus. These include the Peek system from Peek Vision in England, the D-Eye system from Si 14 in Italy, the IExaminer from Welch Allyn, EyeGo from Stanford University and DigiSight Technologies, and Ocular CellScope from the University of California, Berkeley, USA.[69,70] These smart devices can record retinal exams capturing “direct” images or video of the retina (without dilation of pupils, or the +20 D lens).

Home Optic Nerve Imaging: Portable fundus cameras (Carl Zeiss Meditec, Nidek, Topcon, and Volk) have been in use for quite some time, while the Envisu C2300, Leica is a handheld OCT unit. For now, they are operator-dependent, and the latter is unreliable due to unstable image acquisition and susceptibility to motion artifacts and alignment issues.

The Final Frontier: Brain-Computer Interfaces and AI Algorithms: The nGoggle (nGoggle, Inc., San Diego, CA) is a portable, wearable, brain-software interface. It integrates electroencephalogram and electrooculogram systems with a smartphone-based head-mounted display, capturing multifocal steady-state visual-evoked potentials in response to stimuli administered to various loci on the visual field.[71] The global and sectoral nGoggle metrics have been shown to be repeatable and superior to the global and sectoral SAP parameters. This home-based testing provides objective assessment of visual function but is yet to be assessed for longitudinal detection of glaucoma progression.

Various AI strategies across clinical modalities, including platforms that enable structure and functional correlation, promise levels of diagnostic accuracy hitherto unimaginable.[25,72] However, none of the strategies tested so far have gained acceptance for clinical use in glaucoma management. The transition from “black box” to “explainable AI” and focus on precision medicine may help overcome the likely regulatory hurdles and their incorporation into clinical practice.[73,74,75]

The way forward for teleglaucoma is the need for greater ease of use and precision, bridging the discrepancies between clinical standards and home testing, thus enabling high-quality remote care.

Patient-Centered Care and Shared Decision-Making

Patient centricity, QoL, and shared decision making are central to the ethics of current glaucoma practice. Even the WGA consensus defines target IOP as the range at which clinicians judge that progressive disease is unlikely to impair the patient’s QoL.[76,77,78] Consequently, in context of a chronic, predominantly asymptomatic condition such as glaucoma, acknowledging patients’ perspectives and honoring their values and expectations become pivotal in fostering patient-centered communication.[79,80]

Quality of life measures, current and future

The primary objective in managing glaucoma is to safeguard the visual function and QoL of patients. Both the disease and its management (AGMs and surgery) can significantly impair a patient’s QoL. The disease, its diagnosis, and treatment can all negatively impact on the patient’s wellbeing and QoL. A large majority of patients remain asymptomatic, until treatment is instituted. Therefore, patient-reported QoL measures may potentially enhance the understanding between patients and physicians and boost treatment adherence by tailoring treatment approaches to each patient’s unique profile, thereby optimizing long-term prognosis.

As the paternalistic and hierarchical system of medicine is replaced with a partnership of care, even QoL measures must be individualized.[81] The most commonly used QoL measures include the National Eye Institute Vision Function Questionnaires (NEI-VFQ-25 and -51 items), Glaucoma Quality of Life (Glau-QoL) questionnaire, Glaucoma Health Perception Index (G-HPI), Glaucoma Utility Index, Treatment Satisfaction Survey-Intraocular Pressure (TSS-IOP), Comparison of Ophthalmic Medications for Tolerability (COMTOL) questionnaire, Visual Activity Questionnaire (VAQ), Glaucoma Symptom Scale (GSS) questionnaire, and glaucoma-specific QoL questionnaire (GQL-15).[82,83,84]

None of the existing questionnaires are suitable for all uses in glaucoma management and research. The ideal questionnaire must be short, self-administered, and easily understandable and must represent the values and expectations of the patients, including patient-reported outcome measures (PROMs).[85] The GlauCAT™, a recently developed measurement tool, measures the personalised QoL impact of glaucoma, implications of vision loss, and QoL costs of glaucoma therapy. It evaluates multiple domains for QoL assessment using a computerized adaptive testing (CAT) system that administers questions from a calibrated items bank. Depending on the patients’ initial responses, the algorithm chooses and administers questions that elicit the required, optimal information. The test ends when the predefined stop criterion is achieved.[85,86,87]

Adapting to individual patient needs and personalized medicine

Glaucoma, characterized by its multifaceted neurodegenerative nature, may benefit from utilization of validated genetic and metabolic biomarkers. This can facilitate timely intervention in clinics, aiding in prognosis, prediction, and monitoring treatment responses, resulting in better clinical outcomes, preventing blindness.[74,88]

Precision medicine can revolutionize healthcare for both populations and individuals by prompting early detection, refining diagnoses, and customizing treatments. This can enable doctors to identify the most efficacious and least risky therapy and for patients prioritize cost-effectiveness with a minimal decrease in QoL.[89]

This requires clinical, personal, genomic data extraction, aggregation, management, and its analysis for tailoring safer, cost-effective, personalized treatments. Integrating the genomic, metabolic, lifestyle, social, and environmental data for the global population is a mammoth task. While AI hopes to breach the technological barriers to its adoption, the ethical, legal, and regulatory barriers remain a challenge.[90]

Multidisciplinary approach in glaucoma management

The incidence and prevalence of glaucoma increase with advancing age, and glaucoma patients often have multiple comorbidities. These include hypertension (29–48%), coronary artery disease (16–35%), diabetes and thyroid disease (9–17%), asthma (7%), depression (8%), and congestive heart failure (12%).[91,92,93,94,95]

Glaucoma is considered a neurodegenerative disease like Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis and often an associated comorbidity. Other associations include migraine, vasodysregulation, and obstructive sleep apnea.[96]

These comorbidities complicate glaucoma management, requiring multiple assessments and collaborative treatment plans.[92]

Primary care physicians are not only critical in referring patients with risk factors for a glaucoma evaluation; they can improve clinical outcomes by improving medication adherence and recognizing adverse drug reactions and surgical complications.[91]

Furthermore, considering the potential effectiveness of rehabilitation strategies in populations with low vision, it is imperative to employ them in patients with advanced glaucoma with the goal of reducing disability and enhancing QoL. It is important to understand vision rehabilitation requirements, incorporate rehabilitation into the care plans, and understand accessibility to suitable providers capable of delivering the rehabilitation program[97,98] [Fig. 1].

Figure 1.

Stakeholder map for multidisciplinary approach to glaucoma management

Ethical and Socioeconomic Considerations

Ethical dilemmas in glaucoma treatment

The basic principles of bioethics include respect for patient autonomy, beneficence, nonmaleficence, and justice. Also critical is glaucoma practitioners’ fiduciary duty to share all relevant clinical information to enable shared decision making. The pitfalls include ethics of glaucoma screening and research, tailoring treatment offered to the patient based on algorithms that favor population-based economics, instead of individuals’ values and expectations. For example, low risk is not no risk; any estimations of patients’ life expectancy may be wrong, and patients’ perception of QoL may be under- or overestimated.

With valid, multiple treatment options available, the cornerstones are shared decision making, patient centricity, and attempted equitable and distributive justice.[96,97,98]

Addressing health disparities: Accessibility and affordability of glaucoma care

Health disparities in glaucoma are not different from other diseases. Poor, racial/ethnic minorities, those living in remote rural areas, women, and children are at greater risk for glaucoma blindness than the more advantaged social groups.[93,94,95,96] This needs to be the focus of recent advances.

The ongoing effort to prevent glaucoma-related blindness

VISION 2020 – The Right to Sight, a WHO and International Agency for the Prevention of Blindness (IAPB) collaboration, identifies glaucoma as a key thrust area. Its key intervention is capacity building (including infrastructure, technological, and human resource development), in collaboration with local partners by integrating eyecare services into primary healthcare.

The World Glaucoma Association (WGA) and the World Glaucoma Patient Association (WGPA) together launched the annual World Glaucoma Day, on March 6, 2008. The global initiative evolved into the World Glaucoma Week, which brings together all key stakeholders through synchronised events to increase glaucoma awareness.[77]

Conclusion

The current landscape of glaucoma management is rapidly evolving, with innovative diagnostic tools and therapeutic strategies. Collaborative efforts between clinicians, researchers, patients, caregivers, and technology pioneers remain paramount in advancing our understanding of the disease and ensuring personalized and equitable treatment. Continuous assessment of current as well as emerging, diagnostic, and therapeutic strategies is critical for mitigating the burden of glaucoma blindness.

Conflicts of interest:

There are no conflicts of interest.

Funding Statement

Nil.